Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
(e)-methyl 2-(7-chloroquinolin-4-ylthio)-3-(4-hydroxyphenyl)acrylate
- Development stage
- Preclinical
- Lead developer
- Charité Universitätsmedizin Berlin
- Modality
- Small Molecules
01
Overview
(E)-methyl 2-(7-chloroquinolin-4-ylthio)-3-(4-hydroxyphenyl)acrylate, also known as QNACR, is a synthetic small molecule hybrid compound investigated for its dual antimalarial and antineoplastic properties. It combines a 7-chloroquinoline moiety, characteristic of the chloroquine class of antimalarials, with a hydroxyphenyl acrylate group. In the context of malaria, it acts as an inhibitor of β-hematin formation, preventing the detoxification of heme by Plasmodium parasites. In oncology research, particularly in prostate cancer models, the compound has demonstrated multi-target efficacy by reducing cell viability, inhibiting adhesion, migration, and invasion, and suppressing neoangiogenesis and Matrix Metalloproteinase-9 (MMP-9) activity. Preclinical studies in PC-3 xenograft mice showed significant tumor growth reduction.
- Other names
- (E)-methyl 2-(7-chloroquinolin-4-ylthio)-3-(4-hydroxyphenyl)acrylatemethyl (2E)-2-[(7-chloroquinolin-4-yl)sulfanyl]-3-(4-hydroxyphenyl)prop-2-enoate
02
Targets
β-HematinMMP9 (Matrix metalloproteinase-9)
Beyond the preview
Go deeper on (e)-methyl 2-(7-chloroquinolin-4-ylthio)-3-(4-hydroxyphenyl)acrylate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on (e)-methyl 2-(7-chloroquinolin-4-ylthio)-3-(4-hydroxyphenyl)acrylate.